0
Abstract: Slide Presentations |

CONTROL OF AIRWAY INFLAMMATION IS ACHIEVED IN ASTHMA PATIENTS WITH FLUTICASONE PROPIONATE ALONE: ADDING MONTELUKAST PROVIDES NO ADDITIONAL CONTROL OF AIRWAY INFLAMMATION FREE TO VIEW

Paul M. Dorinsky, MD*; Susan Wilson, PhD; Steve Yancey, MS; Donna Reilly, BS; John Stauffer, MD; Lisa Edwards, PhD; Laura Sutton, PharmD; Ratko Djukanovic, MD
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest


Chest. 2005;128(4_MeetingAbstracts):164S-b-165S. doi:10.1378/chest.128.4_MeetingAbstracts.164S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  This randomized, double-blind study evaluated airway inflammation following administration of fluticasone propionate (FP) 100mcg BID or FP 100mcg BID + montelukast (MON) 10mg QD for 12 weeks in 103 subjects with persistent asthma who were symptomatic on short-acting beta2-agonists.

METHODS:  Subjects underwent biopsy and BAL at baseline and after 12 weeks of treatment with FP or FP+MON.

RESULTS:  Furthermore, clinical asthma control, as assessed by AM and PM PEF, FEV1, albuterol use and rescue-free days was similar with FP+MON compared with FP alone.

CONCLUSION:  There was no evidence of incremental improvement in airway inflammation or overall asthma control with the addition of montelukast 10mg QD to FP 100mcg BID.

CLINICAL IMPLICATIONS:  The common practice of adding a leukotriene modifier to current ICS therapy for broader coverage of inflammation is not supported by this study. The broad anti-inflammatory effects of ICS adequately control the underlying airway inflammation of asthma. (FPD40014).

DISCLOSURE:  Paul Dorinsky, Shareholder shareholder of GSK stock; Employee employee of GSK.Median Change at EndpointFP 100 mcg BID (n=53)FP+MON 10mg QD (n=50)p ValueEosinophils* Baseline Change8.93 -8.277.61 -6.880.616Basement membrane thickness (μm) Baseline Change8.21 0.928.99 0.740.743Mast cells*Baseline Change25.22 -5.2429.27 -14.980.005Neutrophils* Baseline Change21.43 19.2221.85 20.920.752CD3+* Baseline Change53.39 -34.0948.12 -49.430.303CD4+* Baseline Change29.41 -21.9424.30 -24.240.603CD8+* Baseline Change20.59 -13.6117.70 -16.500.510CD25+* Baseline Change0.00 -0.470.57 -0.530.266*

Cells in submucosa/mm2;

mean change

Tuesday, November 1, 2005

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543